This is a first in precision medicine. This group aims to be the first to analyze brain scans together with genomic + clinical + phenotypic data to study neurodegenerative diseases at a population level then distill it down to an individual's personal treatment plan. GIRO Health (IBM, RowAnalytics, Martinos Center & Envision Genomics) is an open initiative designed to bring together the best and the brightest to solve complex diseases such as ALS, Alzheimer's, Parkinsons and more.
Cambridge, MA, December 07, 2017 — RowAnalytics Ltd., the Martinos Center for Biomedical Imaging (Martinos Center) and Envision Genomics Inc. today announced that they are combining their world leading technologies and expertise with IBM Power servers, to create a new, open initiative in precision medicine, GIRO Health. This initiative will accelerate understanding of the biology of complex neurological and neurodegenerative diseases to improve diagnosis and personalized treatment options. The collective science, technology and clinical know-how behind GIRO Health brings a first-ever combination of clinical genomics, multi-modal imaging and massively combinatorial data analytics to precision medicine with enormous potential to provide new insights for therapeutic R&D, and more accurate diagnosis and selection of patient therapies.
To date, analysis of complex diseases has been limited by analytical technologies that work on single dimensions of data. However, neurological diseases are complex and multifactorial, with combinations of genetic, phenotypic, clinical and environmental factors playing a role in a patient’s personal disease risk, resulting in different clinical outcomes and therapy responses for patients with the same disease. Characterizing this complex disease biology and identifying the most effective treatments for the patient requires integration of all the latest advances in clinical genomics, biomedical imaging, data analytics and AI technologies into a coherent, scalable and patient focused precision medicine capability.
“GIRO Health will bring together, for the first time, all the components needed to deliver the benefits of precision medicine at scale for complex diseases,” said Steve Gardner, CEO of RowAnalytics. “The strategic integration of the founding partners’ world-leading technologies and their ground-breaking analytical capabilities enables GIRO Health to accelerate and scale the application of precision medicine in neurological and neurodegenerative disorders.”
Research foundations, disease specialists and clinical researchers are invited to collaborate in a collective effort to investigate the underlying mechanisms of action, critical pathways and patient care options to aid those diagnosed with diseases including, but not limited to, ALS, MS, Dementia, Parkinson’s Disease, Tuberous Sclerosis and Epilepsy.
Bill Shaw, Executive Director of the Martinos Center adds, “We are excited to be integrating state-of-the-art biomedical imaging, genomics, analytics and artificial intelligence technologies in the pursuit of better therapeutic options for patients with complex, multi-factorial neurological diseases.”
GIRO Health will radically transform the scale, speed and accuracy of precision medicine research, and empower and ultimately deliver better health outcomes for patients. It will deliver an end-to-end precision medicine capability, researching new disease diagnostics and therapies, developing patient stratification and clinical decision support systems, and building personalized, patient focused tools that enable them to change aspects of their lifestyle and take more control of their own health.
“The complexity of this challenge requires a multi-disciplinary team with complementary technologies and an unwavering focus on the patient and their needs,” said Grace Terrell, CEO of Envision. “The partners bring together world-class genomic data analysis and clinical interpretation, high-performance computing and storage, digital health tools and experience of redesigning patient-focused healthcare models.”
The reference architecture for GIRO Health will be built on IBM’s current and future Power Systems, which will provide the outstanding performance, GPU acceleration and scaling required to generate faster insights and better patient outcomes. “IBM has been privileged to work with this team. We believe that IBM’s high-performance compute, parallel file system and resources schedulers provide the foundational architecture needed to build a truly scalable platform,” said Janis Landry-Lane, Global Sales, IBM Systems. Bruce Jones, IBM Technology Evangelist adds, “Precision Medicine is critical for the future of medicine, and this collaborative initiative with GIRO Health will have a huge impact in both the clinic and personal management of disease.”
GIRO Health will be operational in the fourth quarter of 2017, and will be based initially at the Charlestown Navy Yard in Boston.
RowAnalytics is an A.I. solutions company innovating analytics to solve grand challenges in health, food and smart living. Our precisionLIFE platform powers massive disease population studies to identify novel associations of multiple genomic, phenotypic and clinical factors in parallel to assess disease risk and predict therapeutic response. Our platform is a remarkable new capability in precision medicine with unprecedented scale and speed to identify biomarkers, find new purposes for existing drugs and to identify those patients most likely to respond to treatment. RowAnalytics’ solutions provide personalization at the scale required to deliver next generation precision medicine, digital health and smart IoT solutions. Headquartered in Oxford, UK, with offices in Copenhagen, DK, Warsaw, PL and Cambridge, MA, RowAnalytics was founded by a diverse team of highly experienced life science, healthcare, A.I. and computer science leaders. To learn more, visit www.rowanalytics.com
About Martinos Center
The Athinoula A. Martinos Center for Biomedical Imaging is one of the world’s premier research centers devoted to development and application of advanced biomedical imaging technologies. Major areas of technology development are magnetic resonance imaging, positron emission tomography, optical imaging and other imaging modalities. Major areas of application research include psychiatric, neurologic & neurovascular disorders, cognitive neuroscience, cardiovascular disease, and cancer. The Martinos Center was established in 2000 by the Harvard-MIT Division of Health Sciences & Technology (HST) and the Massachusetts General Hospital (MGH). It has around 120 faculty members and more than 100 postdoctoral research fellows and graduate students.
To learn more, visit www.martinos.org
About Envision Genomics
Envision Genomics is a clinical genomics services platform headquartered in Huntsville, AL. delivering end-to-end precision medicine to the undiagnosed, rare disease patient population. The Company brings comprehensive genetic testing services (whole genome and whole exome sequencing), big data analytics, patient intake processes, and whole-person care models to the medically expensive and complex-to-manage, rare or undiagnosed disease patient population in partnership with health systems, physicians, and payers. Envision is building a network of children’s hospitals and empowering them to practice genomic medicine by providing the end-to-end expertise, infrastructure and resources necessary to implement and deploy clinical genomics.
To learn more, visit www.envisiongenomics.com
IBM Power Systems are servers designed for mission-critical applications and emerging Cognitive Era workloads including artificial intelligence, machine learning, deep learning, advanced analytics and high performance computing. Designed to deliver efficiency whether deployed in a private, public and hybrid cloud, Power Systems benefit from a wide range of open technologies, many stemming from collaboration with fellow OpenPOWER Foundation members.
To learn more visit: www.ibm.com/power
RowAnalytics Ltd – Loralyn Mears, +1 804-539-2324, [email protected]
Martinos Center – Bill Shaw, +1 617-643-3724, [email protected]
Envision Genomics – Aaron Fisher, +1 256-327-0535, [email protected]
Powered by WPeMatico